Who are the top shareholders of the Dr Lalchand. Lab?

The top shareholder of Dr Lalchand Lab is Arjan Lal Chandani, with a 42.53% stake, followed by public shareholder Amit Charan at 5.08%. Individual investors own 45.68% of the company, with no institutional or pledged promoter holdings.

The top shareholders of Dr Lalchand Lab include Arjan Lal Chandani, who holds the largest stake at 42.53%. Following him, the highest public shareholder is Amit Charan, with a holding of 5.08%. Additionally, individual investors collectively own 45.68% of the company. Notably, there are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

how big is Dr Lalchand. Lab?

As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, classifying it as a Micro Cap company, with shareholder's funds of 9.54 Cr and total assets of 14.99 Cr; however, no recent financial data is available for the latest four quarters.

Market Cap: As of Jun 06, Dr Lalchandani Labs Ltd has a market capitalization of 6.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds are valued at 9.54 Cr, and the Total Assets amount to 14.99 Cr.

Who are in the management team of Dr Lalchand. Lab?

As of March 2022, the management team of Dr Lalchand Lab includes Arjan Lalchandani (Chairman & Managing Director), Mohit Lalchandani (Whole Time Director & CEO), Anchal Gupta (Executive Director & CFO), and independent directors Rajiv Handa and Prakash Jhuraney, along with director Swati Chandra.

As of March 2022, the management team of Dr Lalchand. Lab includes the following individuals:<BR><BR>1. Arjan Lalchandani - Chairman & Managing Director<BR>2. Mohit Lalchandani - Whole Time Director & CEO<BR>3. Anchal Gupta - Executive Director & CFO<BR>4. Rajiv Handa - Independent Director<BR>5. Prakash Jhuraney - Independent Director<BR>6. Swati Chandra - Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Dr Lalchand. Lab do?

Dr Lalchandani Labs Ltd provides pathology laboratory services and operates as a micro-cap company with a market cap of Rs 6 Cr. It was established in 2011 and transitioned to a limited company in 2017.

Overview: <BR>Dr Lalchandani Labs Ltd operates in the healthcare services industry, specifically providing pathology laboratory services, and is classified as a micro-cap company.<BR><BR>History: <BR>Dr Lalchandani Labs Ltd was originally incorporated as a partnership firm in New Delhi on 15 September 2011 under the name Dr. A Lalchandani Pathology Laboratories. The partnership was taken over by Dr Lalchandani Labs Ltd on 2nd August 2017, as per the agreement dated 31st August 2017. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 6 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 6.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 4.40% <BR>Price to Book: 0.64<BR><BR>Contact Details: <BR>Address: M-20 Basement, Greater Kailash-1, New Delhi, 110048 <BR>Tel: 91-11-49057058 <BR>Email: info@lalchandanipathlab.com <BR>Website: http://www.lalchandanipathlab.com

Has Dr Lalchand. Lab declared dividend?

No Dividend History Available

Who are the peers of the Dr Lalchand. Lab?

Dr. Lalchand Lab's peers include Syngene Intl., Dr. Lal Pathlabs, and Metropolis Health, among others. It has average management risk and below-average growth, with a 1-year return of -42.86%, significantly lower than its peers.

Peers: The peers of Dr Lalchand. Lab are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Average management risk is noted for Vimta Labs and Dr Lalchand. Lab, while Below Average management risk is seen at Suven Life Scie. In terms of Growth, Excellent growth is found at Vimta Labs, while Average growth is observed at Poly Medicure, Indegene, and the rest. Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Dr Lalchand. Lab, and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.15%, while Dr Lalchand. Lab has the lowest at -42.86%. This indicates that Dr Lalchand. Lab's performance is significantly lower than its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Metropolis Healt, and Dr Lalchand. Lab.

What is the technical trend for Dr Lalchand. Lab?

As of June 2, 2025, Dr. Lalchand Lab's trend is mildly bearish, influenced by daily moving averages and mixed signals from MACD and Bollinger Bands, with weekly indicators showing mild bullishness and monthly indicators remaining bearish.

As of 2 June 2025, the technical trend for Dr Lalchand. Lab has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The daily moving averages are mildly bearish, while the weekly Bollinger Bands are bullish, contrasting with the monthly Bollinger Bands that are mildly bearish. The KST shows a mildly bullish stance on the weekly chart but is bearish on the monthly. Dow Theory indicates no trend on the weekly and mildly bullish on the monthly. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the mixed signals from MACD and Bollinger Bands.

Is Dr Lalchand. Lab overvalued or undervalued?

As of September 19, 2025, Dr Lalchand Lab is considered undervalued with a PE ratio of 9.97 and an EV to EBITDA of 10.33, significantly lower than peers like Apollo Hospitals and Max Healthcare, and has outperformed the Sensex with a year-to-date return of 36.15%.

As of 19 September 2025, the valuation grade for Dr Lalchand Lab has moved from expensive to attractive, indicating a significant shift in its market perception. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 9.97, an EV to EBITDA of 10.33, and a Price to Book Value of 1.00, which are notably lower than many peers in the healthcare sector.<BR><BR>In comparison, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even higher at a PE of 93.83 and an EV to EBITDA of 58.13, highlighting the relative attractiveness of Dr Lalchand Lab. The company's recent stock performance has also shown resilience, with a year-to-date return of 36.15%, significantly outperforming the Sensex's 5.74% during the same period.

When is the next results date for Dr Lalchand. Lab?

Dr Lalchand. Lab will announce its results on 14 November 2025.

Dr Lalchand. Lab is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Dr Lalchand. Lab?

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Answer:<BR>The historical performance of Dr Lalchand. Lab shows a declining trend in net sales and profitability over the past few years, with a significant drop in total operating income from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. The operating profit margin has fluctuated, peaking at 28.9% in Mar'24 before falling to 23.37% in Mar'25. Profit before tax also saw a decline, moving from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax decreased from 0.93 Cr in Mar'22 to 0.42 Cr in Mar'25. The company’s total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, and total liabilities also saw a reduction from 18.12 Cr to 15.75 Cr in the same period. Cash flow from operating activities has been stagnant, with no inflow reported in the last two years, although there was a net cash inflow of 1.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Dr Lalchand. Lab's financial performance has shown a notable decline in net sales, which decreased from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25. This decline is reflected in the total operating income, which also fell significantly over the years. The operating profit margin peaked at 28.9% in Mar'24 but dropped to 23.37% in Mar'25, indicating challenges in maintaining profitability. Profit before tax decreased from 1.25 Cr in Mar'22 to 0.40 Cr in Mar'25, while profit after tax followed a similar trend, moving from 0.93 Cr to 0.42 Cr. The company's total assets decreased from 18.12 Cr in Mar'22 to 15.75 Cr in Mar'25, with total liabilities also reducing in the same timeframe. Cash flow from operating activities has remained stagnant, with no inflow in recent years, although a net cash inflow of 1.00 Cr was recorded in Mar'25, suggesting some improvement in liquidity.

Which are the latest news on Dr Lalchand. Lab?

Why is Dr Lalchand. Lab falling/rising?

As of 19-Nov, Dr Lalchandani Labs Ltd is priced at Rs 20.23, with no change and underperforming its sector by 3.4%. The stock has shown erratic trading patterns and declining investor participation, indicating negative market sentiment.

As of 19-Nov, Dr Lalchandani Labs Ltd is currently priced at Rs 20.23, showing no change (0.00%). The stock has underperformed its sector by 3.4% today and opened with a loss of 4.98%, reaching an intraday low of Rs 20.23. The trading activity has been erratic, with the stock not trading on 3 out of the last 20 days. Additionally, the weighted average price indicates that more volume was traded close to the low price, and there has been a notable decline in investor participation, with delivery volume falling by 23.08% against the 5-day average. There is no information available regarding positive or negative factors impacting the stock.<BR><BR>Broader market context is not available as the stock vs benchmark returns data is missing. However, the stock's performance today suggests a negative sentiment in the market, as indicated by its significant drop and underperformance relative to its sector. The liquidity of the stock appears to be adequate for trading, but the overall decline in investor participation and the erratic trading pattern may contribute to a lack of confidence among investors, further impacting the stock's price negatively.